Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
AdAlta Limited (1AD.AX)
AUD0.00
+0.00 (+0.00%)
AU ASX Healthcare Biotechnology
Address
Shop 14 330 Collins St 3083
Melbourne, VIC, AU
Melbourne, VIC, AU
CEO
Timothy Charles Oldham
Website
adalta.com.au
IPO
2016-08-22
ISIN AU0000001AD2
Description
AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF) and other related fibrotic diseases. The company has forged strategic alliances, including a collaboration with GE Healthcare to identify i-bodies that bind to granzyme B, and a partnership with Carina Biotech Pty Ltd. focused on developing CAR-T cell products designed to target various solid tumor antigens. AdAlta Limited was founded in 2006 and is headquartered in Bundoora, Australia.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
AUD0.00
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
3M
Beta
0.19
Float Shares
145.01M
Free Float %
23.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | -20.00% | -20.00% | +0.00% | -86.67% | +33.33% | -86.67% | -98.33% | -99.71% | -99.85% | -99.85% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-56.65
Distress
Piotroski F-Score
1 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
C+
Overall Score
2 / 5
Medium
DCF Score
4 / 5
High
ROE Score
5 / 5
High
ROA Score
1 / 5
Low
D/E Score
1 / 5
Low
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-61.0% Q4'25: -100.0% (vs Q4'23)
-
EPS growth Biotechnology: +29.7%+36.7% ★ Q4'25: +95.2% (vs Q4'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-471.1%
-
EBIT margin Biotechnology: +0.0%-659.1%
-
ROIC Biotechnology: -16.1%— Q4'25: +504.1% (vs Q4'23)
-
Share dilution Biotechnology: -3.4%+32.0% Q4'25: +1,622.3% (vs Q4'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.40× Q4'25: 0.00× (vs Q4'23)
Valuation Multiples
From
To
Consensus Estimates
| Metric |
Jun 2019 actual |
Jun 2020 actual |
Jun 2021 actual |
Jun 2022 actual |
Jun 2023 actual |
Jun 2026 1 Rev. Ana. 1 EPS Ana. |
Jun 2027 1 Rev. Ana. 1 EPS Ana. |
Jun 2028 1 Rev. Ana. 1 EPS Ana. |
Jun 2029 1 Rev. Ana. 1 EPS Ana. |
Jun 2030 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
3.54M
est: 3.59M (-1.4%)
|
3.83M
est: 1.73M (+121.1%)
|
848.2K
est: 3.24M (-73.9%)
|
2.75M
est: 3.17M (-13.1%)
|
3.47M
est: 3.20M (+8.4%)
|
3.59M
3.59M – 3.59M
+12.2% YoY
|
1.73M
1.73M – 1.73M
-51.8% YoY
|
3.24M
3.24M – 3.24M
+87.3% YoY
|
3.17M
3.17M – 3.17M
-2.3% YoY
|
3.20M
3.20M – 3.20M
+1.0% YoY
|
| EBITDA |
-9.38M
est: -3.59M (-161.4%)
|
-5.80M
est: -1.73M (-234.8%)
|
-8.36M
est: -109.27M (+92.4%)
|
-7.31M
est: -3.17M (-130.7%)
|
-7.58M
est: -3.20M (-137.0%)
|
-3.59M
-3.59M – -3.59M
-12.2% YoY
|
-1.73M
-1.73M – -1.73M
+51.8% YoY
|
-3.24M
-3.24M – -3.24M
-87.3% YoY
|
-3.17M
-3.17M – -3.17M
+2.3% YoY
|
-3.20M
-3.20M – -3.20M
-1.0% YoY
|
| EBIT |
-9.42M
est: -3.59M (-162.3%)
|
-5.89M
est: -1.73M (-240.2%)
|
-8.39M
est: -102.72M (+91.8%)
|
-7.34M
est: -3.17M (-131.7%)
|
-7.61M
est: -3.20M (-137.9%)
|
-3.59M
-3.59M – -3.59M
-12.2% YoY
|
-1.73M
-1.73M – -1.73M
+51.8% YoY
|
-3.24M
-3.24M – -3.24M
-87.3% YoY
|
-3.17M
-3.17M – -3.17M
+2.3% YoY
|
-3.20M
-3.20M – -3.20M
-1.0% YoY
|
| Net Income |
-5.92M
est: -5.33M (-11.0%)
|
-6.01M
est: -2.01M (-199.4%)
|
-5.63M
est: -106.00M (+94.7%)
|
-6.06M
est: -3.29M (-84.1%)
|
-4.85M
est: -3.32M (-45.9%)
|
-5.33M
-5.33M – -5.33M
-60.4% YoY
|
-2.01M
-2.01M – -2.01M
+62.4% YoY
|
-2.66M
-2.66M – -2.66M
-32.7% YoY
|
-3.29M
-3.29M – -3.29M
-23.7% YoY
|
-3.32M
-3.32M – -3.32M
-1.0% YoY
|
| SGA |
1.23M
est: 8.36M (-85.2%)
|
2.44M
est: 4.03M (-39.4%)
|
2.94M
est: 7.55M (-61.1%)
|
4.33M
est: 7.38M (-41.3%)
|
4.19M
est: 7.45M (-43.8%)
|
8.36M
8.36M – 8.36M
+12.2% YoY
|
4.03M
4.03M – 4.03M
-51.8% YoY
|
7.55M
7.55M – 7.55M
+87.3% YoY
|
7.38M
7.38M – 7.38M
-2.3% YoY
|
7.45M
7.45M – 7.45M
+1.0% YoY
|
| EPS |
-0.28
est: -0.04 (-595.5%)
|
-0.18
est: -0.02 (-1,058.9%)
|
-0.12
est: -0.02 (-483.9%)
|
-0.11
est: -0.03 (-332.5%)
|
-0.08
est: -0.03 (-198.6%)
|
-0.04
-0.04 – -0.04
-60.4% YoY
|
-0.02
-0.02 – -0.02
+62.4% YoY
|
-0.02
-0.02 – -0.02
-32.7% YoY
|
-0.03
-0.03 – -0.03
-23.7% YoY
|
-0.03
-0.03 – -0.03
-1.0% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-28 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-27 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-26 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-25 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-22 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-21 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-19 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-18 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-15 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-13 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-12 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-11 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-08 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C+ | 2/5 | 3/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C+ | 2/5 | 4/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-6.60M
OE per share TTM
-0.05
Owner's Yield
-105.43%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
4.1%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
-5.0K
Shares Outstanding
608.07M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Timothy Charles Oldham | Chief Executive Officer, MD & Director | 371.9K | — |
| Angus Tester | Senior Director of Operations | — | male |
| Cameron Jones | Company Secretary | — | male |
| Andrew O'Brien | Head of Corporate Development | — | male |
| Kevin Patrick Lynch FFPM MBBS | Consultant Chief Medical Officer of Oncology | — | — |
| Michael Foley | Founding Chief Scientist | — | — |
| Janette Dixon | Head of Business Development | — | female |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 1AD.AX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
